RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells

Drug Delivery and Translational Research

Volumn 5, Issue 1, 2015, Pages 15-26

  Shan, Dan ^a   Li, Jason ^a   Cai, Ping ^a   Prasad, Preethy ^a   Liu, Franky ^a   Rauth, Andrew Michael ^b   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cell adhesion; Cell invasion; Metastasis; RGD conjugated solid lipid nanoparticle; Triple negative breast cancer cell; v 3 integrin receptor

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; FIBRONECTIN; MACROGOL; SOLID LIPID NANOPARTICLE; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; LIPID; MACROGOL DERIVATIVE; MACROGOL STEARATE; NANOPARTICLE; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER LOCALIZATION; CELL ADHESION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; TUMOR INVASION; ANIMAL; BREAST TUMOR; CELL MOTION; CHEMISTRY; DRUG EFFECTS; FEMALE; METABOLISM; NUDE MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; LIPIDS; MICE, NUDE; NANOPARTICLES; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 84921909998     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-014-0210-2     Document Type: Article

References (44)

1. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.
2. Assoian RK, Klein EA. Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol. 2008;18(7):347–52.
3. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264(5158):569–71.
4. Felding-Habermann B, O’Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A. 2001;98(4):1853–8.
5. Huveneers S, van den Bout I, Sonneveld P, Sancho A, Sonnenberg A, Danen EH. Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src. Cancer Res. 2007;67(6):2693–700.
6. Kumar CC, Armstrong L, Yin Z, Malkowski M, Maxwell E, Ling H, et al. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol. 2000;476:169–80.
7. Pytela R, Pierschbacher MD, Ruoslahti E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell. 1985;40(1):191–8.
8. Chen K, Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics. 2011;1:189–200.
9. Wang Z, Chui WK, Ho PC. Integrin targeted drug and gene delivery. Expert Opin Drug Deliv. 2010;7(2):159–71.
10. Miura Y, Takenaka T, Toh K, Wu S, Nishihara H, Kano MR, et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood–brain tumor barrier. ACS Nano. 2013;7(10):8583–92.
11. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release. 2010;143(1):136–42.
12. Shen M, Huang Y, Han L, Qin J, Fang X, Wang J, et al. Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. J Control Release: Off J Control Release Soc. 2012;161(3):884–92.
13. Jiang X, Xin H, Gu J, Xu X, Xia W, Chen S, et al. Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials. 2013;34(6):1739–46.
14. van de Ven AL, Kim P, Haley O, Fakhoury JR, Adriani G, Schmulen J, et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release: Off J Control Release Soc. 2012;158(1):148–55.
15. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104(39):15549–54.
16. Choi CHJ, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010;107(3):1235–40.
17. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong KL, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732–40.
18. Shuhendler AJ, Prasad P, Leung M, Rauth AM, Dacosta RS, Wu XY. A novel solid lipid nanoparticle formulation for active targeting to tumor alpha(v) beta(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater. 2012;1(5):600–8.
19. Georgoulis A, Havaki S, Drosos Y, Goutas N, Vlachodimitropoulos D, Aleporou-Marinou V, et al. RGD binding to integrin Alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures. Ultrastruct Pathol. 2012;36(6):387–99.
20. Li S, Wei J, Yuan L, Sun H, Liu Y, Zhang Y, et al. RGD-modified endostatin peptide 30 derived from endostatin suppresses invasion and migration of HepG2 cells through the alphavbeta3 pathway. Cancer Biother Radiopharm. 2011;26(5):529–38.
21. Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol. 1988;106(3):925–30.
22. Elias DR, Poloukhtine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine. 2012.
23. Hak S, Helgesen E, Hektoen HH, Huuse EM, Jarzyna PA, Mulder WJ, et al. The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano. 2012;6(6):5648–58.
24. Waite CL, Roth CM. Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density. Biotechnol Bioeng. 2011;108(12):2999–3008.
25. Shuhendler AJ, Prasad P, Chan HK, Gordijo CR, Soroushian B, Kolios M, et al. Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue. ACS Nano. 2011;5(3):1958–66.
26. Humphries JD, Schofield NR, Mostafavi-Pour Z, Green LJ, Garratt AN, Mould AP, et al. Dual functionality of the anti-beta1 integrin antibody, 12G10, exemplifies agonistic signalling from the ligand binding pocket of integrin adhesion receptors. J Biol Chem. 2005;280(11):10234–43.
27. Belvisi L, Riccioni T, Marcellini M, Vesci L, Chiarucci I, Efrati D, et al. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther. 2005;4(11):1670–80.
28. Humphries MJ. Cell adhesion assays. Methods Mol Biol. 2009;522:203–10.
29. Moutasim KA, Nystrom ML, Thomas GJ. Cell migration and invasion assays. Methods Mol Biol. 2011;731:333–43.
30. Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, Lin EC, et al. Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis. 1998;16(1):50–61.
31. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81(1):136–47.
32. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker Jr JR, Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol. 2007;14(1):107–15.
33. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker Jr JR. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun (Camb). 2005(46):5739–41.
34. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197:3–53.
35. Grobmyer SR, Zhou G, Gutwein LG, Iwakuma N, Sharma P, Hochwald SN. Nanoparticle delivery for metastatic breast cancer. Nanomedicine. 2012;8 Suppl 1:S21–30.
36. Shokeen M, Pressly ED, Hagooly A, Zheleznyak A, Ramos N, Fiamengo AL, et al. Evaluation of multivalent, functional polymeric nanoparticles for imaging applications. ACS Nano. 2011;5(2):738–47.
37. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4(128):128ra39.
38. Bauer K, Mierke C, Behrens J. Expression profiling reveals genes associated with transendothelial migration of tumor cells: a functional role for alphavbeta3 integrin. Int J Cancer. 2007;121(9):1910–8.
39. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res. 2005;25(1A):79–83.
40. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627–36.
41. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–92.
42. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med. 2007;48(7):1162–71.
43. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem. 2009;20(12):2199–213.
44. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463–78.